Pacific Capital Partners’s Royalty Pharma RPRX Stock Holding History

Pacific Capital Partners’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-94,750	Closed	-$3.66M	–	62
2025 Q4	$3.66M	Sell	94,750 -5,250	-5%	-$200K	3.89%	10
2025 Q3	$3.53M	Buy	100,000 +2,500	+3%	+$90.5K	3.93%	10
2025 Q2	$3.51M	Sell	97,500 -77,500	-44%	-$2.57M	3.29%	12
2025 Q1	$5.45M	Buy	175,000 +12,500	+8%	+$396K	3.45%	12
2024 Q4	$4.15M	Hold	162,500	–	–	2.44%	16
2024 Q3	$4.6M	Hold	162,500	–	–	2.69%	13
2024 Q2	$4.29M	Hold	162,500	–	–	2.84%	12
2024 Q1	$4.94M	Buy	162,500 +12,500	+8%	+$369K	3.23%	11
2023 Q4	$4.21M	Sell	150,000 -21,500	-13%	-$591K	3.18%	11
2023 Q3	$4.65M	Buy	+171,500	New	+$5.09M	2.81%	13

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Pacific Capital Partners's RPRX Position: Q1 2026 in Review

Pacific Capital Partners sold out of Royalty Pharma (RPRX) in Q1 2026, closing a stake of 94,750 shares — an estimated $3.66M sold.

Pacific Capital Partners first reported a position in RPRX in Q3 2023 and held it in 10 quarters. The position peaked at $5.45M in Q1 2025. 590 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

Pacific Capital Partners reported no remaining Royalty Pharma position as of Q1 2026 after selling out during the quarter.
Pacific Capital Partners sold 94,750 Royalty Pharma shares in Q1 2026, an estimated $3.66M.
Pacific Capital Partners first reported a position in Royalty Pharma in Q3 2023 and held it in 10 quarters.
Pacific Capital Partners's Royalty Pharma position peaked at $5.45M in Q1 2025.
590 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Pacific Capital Partners's 13F filing for Q1 2026, filed 9 Apr 2026.